Skye Bioscience Inc.(US:SKYE) Prnewswire·2025-12-11 14:00Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Skye Bioscience, Inc. regarding a class action lawsuit due to allegations of misleading statements related to the company's lead product candidate, nimacimab [1]. Group 1: Allegations and Class Period - The class period for the allegations is from November 4, 2024, to October 3, 2025 [1]. - The complaint alleges that the defendants made materially false and/or misleading statements about nimacimab, claiming it was more effective than it actually is [1]. - It is stated that the clinical, regulatory, and commercial prospects of nimacimab were overstated, leading to misleading public statements [1]. Group 2: Next Steps for Shareholders - Shareholders are encouraged to register for the class action by January 16, 2026, to potentially be appointed as lead plaintiff [2]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the case [2]. - Participation in the case incurs no cost or obligation for the shareholders [2]. Group 3: About the Gross Law Firm - The Gross Law Firm is a nationally recognized class action law firm focused on protecting investors' rights against deceit and fraud [3]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [3].